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Abstract Collagen XXV alpha 1 (COL25A1) is a collag-
enous type II transmembrane protein purified from senile
plaques of Alzheimer’s disease (AD) brains. COL25A1
alleles have been associated with increased risk for AD in a
Swedish population. COL25A1 is specifically expressed in
neurons and binds to aggregated Aβ in vitro. However, its
contribution to the pathogenesis of AD and in vivo function
are unknown. Here, we report that over-expression of
COL25A1 in transgenic mice increases p35/p25 and β-site
APP-cleaving enzyme 1 (BACE1) levels, facilitates intra-
cellular aggregation and extracellular matrix deposits of
Aβ, and causes synaptophysin loss and astrocyte activation.
COL25A1 mice displayed reduced anxiety-like behavior in
elevated plus maze and open field tests and significantly
slower swimming speed in Morris water maze. In stable cell
lines, motifs in noncollagenous domains of COL25A1 were
important for the induction of BACE1 expression. These
findings demonstrate that COL25A1 leads to AD-like
pathology in vivo. Modulation of COL25A1 function may
represent an alternative therapeutic intervention for AD.
Keywords COL25A1 . Alzheimer’s disease . Amyloidβ .
BACE1 . p25 . Cdk5
Introduction
According to the prevailing “amyloid cascade” hypothesis,
the pathogenesis of Alzheimer’s disease (AD) is driven
primarily by amyloidosis, a gradual abnormal accumulation
of Aβ [1]. Aβ is a proteolytic product of amyloid precursor
protein (APP) metabolism, generated by sequential cleavage
by β-secretase (β-site APP-cleaving enzyme 1, BACE1) and
γ-secretase. Dysfunction of BACE1 and γ-secretase inevi-
tably causes aberrant APP processing, production of toxic
Aβ species, and amyloidogenesis. Although no BACE1
mutation has been identified in AD, BACE1 protein and
activity levels are significantly increased in AD brains [2],
and elevated BACE1 levels increase Aβ production in
BACE1 transgenic (TG) mice [3, 4]. Aβ is produced as a
monomer, but readily aggregates to form oligomeric com-
plexes, and further assembles to form fibrils.
Dysregulation of cyclin-dependent kinase 5 (Cdk5) has
been suggested to be one of the downstream processes
affected by Aβ toxicity [5, 6]. Cdk5 is expressed in most
tissues, but its neuron-specific activator p35/p25 restricts its
activity largely to neurons. p25 and Cdk5 activities are
increased in human AD brains [7, 8]. Elevated p25 was
recently shown to increase Aβ production, an effect that
was mediated by an increase in BACE1 levels and reversed
with a pharmacological inhibitor [9, 10]. These data
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demonstrate a positive regulatory loop between Aβ and
p35/p25.
Collagen XXV alpha 1 (COL25A1), also known as
collagen-like Alzheimer’s amyloid plaque component pre-
cursor, is a newly identified type II transmembrane protein
specifically expressed in neurons that colocalizes with Aβ
in senile plaques in AD brains [11, 12]. Previously, a
modest association between SNPs of COL25A1 and
increased AD risk was reported in a Swedish population
[13]. The primary structure of COL25A1 is composed of
three collagenous domains (COL1–3) flanked by four
noncollagenous domains (NC1–4). The N-terminal NC1
domain contains a short cytoplasmic domain, a transmem-
brane domain, and an extracellular ectodomain which
harbors a furin cleavage site. Proteolytic processing by
furin releases the COL25A1 C-terminus to the extracellular
matrix. COL25A1 binds specifically to Aβ fibrils in vitro,
slows their elongation, and facilitates their assembly into
aggregates with increased resistance to proteases [14–16]. It
is not known whether COL25A1 contributes to the
pathogenesis of AD in vivo.
To investigate the role of COL25A1 in the pathogenesis
of AD, we assessed the effects of COL25A1 over-
expression on Aβ, p35/p25, and BACE1 levels in TG
mice. The effect on synaptophysin and astrocyte were
examined. We also carried out behavioral analyses. In
addition, we evaluated the importance of NC1, NC2, and
NC3 domains of COL25A1 in the induction of BACE1 in
stably transfected SH-SY5Y cell lines. Our findings
provide in vivo evidence that COL25A1 plays a critical
role in AD pathogenesis.
Materials and methods
Generation of TG mice
Human COL25A1 complementary DNA (cDNA; GenBank
accession no. AF293340 nt507–2588, splice variant with-
out nt952–969; corresponding protein AAK35008 without
aa141–146 in COL1 domain) was amplified and subcloned
into a Thy-1.2 expression cassette (kind gift from Dr.
Corinna Schneider) at a XhoI site. Transgenic founders
were produced on a (C57BL/6 X SJL) F2 background. Two
pairs of primers were used to identify and confirm TG
mice: CLAC6f: 5′-GATGGAGAGCCTGGTC TTGATG-3′
and CLAC6r: 5′-GGATGATGGCATGCAGCACTG-3′
(polymerase chain reaction (PCR) product, 335 bp); and
CLAC7f: 5′-CCTTGGCTTTCTCTGAGTGGCA-3′ and
CLAC5r: 5′-AGTCGCTCCACTTT CTCTTGCAC-3′
(PCR product, 491 bp). Two founders (861 and 797) with
abundant transgene expression were selected and back-
crossed onto the C57BL/6J (Charles River Laboratories)
background. The studies reported here were all conducted
on line 861; some findings were confirmed in line 797.
Immunostaining
Immunohistochemical staining was performed as described
[17] with slight modifications. Free-floating 20-µm
coronal sections were collected serially into cryoprotec-
tant medium (30% glycerol/30% ethylene-glycol in
phosphate-buffered saline) and kept at −20°C. Sections
were pretreated with 1% H2O2/10% methanol/phosphate-
buffered saline for 10 min at room temperature to quench
endoperoxidase activity. The primary antibodies were
rabbit anti-NC4 (1:600, kind gift from Dr. Takeshi
Iwatsubo), rabbit anti-human beta-amyloid 1-40/42
(AB5076, Chemicon, Temecula, CA, USA; 1:200) [18,
19], mouse anti-BACE1 (MAB5308, Chemicon; 1:500),
rabbit anti-cdk5r1(p35) (sc-820, C-19, Santa Cruz
Biotechnology, Santa Cruz, CA, USA; 1:100), and
mouse anti-glial fibrillary acidic protein (GFAP;
MAB360, Chemicon; 1:600). The secondary antibodies
were biotinylated goat anti-rabbit or mouse IgG (Vector
Laboratories, Burlingame, CA, USA; 1:500). Reaction
products were visualized with the ABC Elite kit (Vector
Laboratories), diaminobenzidine, and H2O2. Sections were
then mounted, dehydrated, cleared, and cover-slipped
with Cytoseal-60 (Electron Microscopy Science, Hat-
field, PA, USA). For immunofluorescence staining, Cy3-
conjugated AffiniPure goat anti-rabbit IgG (Jackson
Immuno Research Laboratories, West Grove, PA, USA)
was used as the secondary antibody.
Western blotting
Snap-frozen forebrain samples were homogenized in crude
extraction buffer (20 mM Tris–HCl, pH 7.4, 5 mM ethyl-
enediamine tetraacetic acid (EDTA), 150 mM NaCl, 1%
Triton X-100) with an EDTA-free protease inhibitor
cocktail (Complete, Roche, Indianapolis, IN, USA). SH-
SY5Y cells were harvested in cold phosphate-buffered
saline from 90-mm dishes and snap frozen. Clones were
collected in modified RIPA buffer (25 mM Tris–HCl, pH
7.6, 5 mM EDTA, 150 mM NaCl, 1%Triton X-100, 0.1%
sodium dodecyl sulfate, 1% deoxycholate, 1 mM phenyl-
methylsulfonyl fluoride) with protease inhibitor cocktail
and centrifuged at 15,000 rpm for 15 min. The supernatants
were collected, and protein concentrations were determined
by BCA protein assay (Pierce, Rockford, IL, USA).
Samples were separated on standard sodium dodecyl
sulfate-polyacrylamide gels, transferred to membranes,
and analyzed by Western blotting. The primary antibodies
were mouse anti-synaptophysin (MAB5258,Chemicon;
1:4,000), mouse anti-BACE1 (MAB5308, Chemicon;
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1:1,000), mouse anti-α-tubulin (Sigma-Aldrich, St. Louis,
MO, USA; 1:1,000,000) or mouse anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; MAB374A, Chemi-
con; 1:80,000). Secondary antibodies were horseradish
peroxidase-labeled goat anti-mouse IgG (sc-2005, Santa
Cruz Biotechnology; 1:2,000). Labeling was detected with
the ECL system (Amersham Biosciences, Pittsburgh, PA,
USA). Densitometric software (Kodak ID 3.6) was used to
quantify bands relative to the endogenous control (tubulin
or GAPDH), and the values were normalized to those of
wild-type (WT) controls.
Behavioral tests
Age-matched 12–20-month-old male COL25A1 TG (n=13)
and non-TG littermates (n=22) underwent a series of
behavioral tests. The experimenter was blinded to the
genotypes during testing. First, mice were tested in an
elevated, plus-shaped maze consisting of two open arms
and two closed arms equipped with rows of infrared
photocells interfaced with a computer (Hamilton-Kinder,
Poway, CA, USA). Briefly, mice were placed individually
in the center of the maze and allowed free access for
10 min. The time spent and distance moved in each of the
arms and the number of times the mice extended over the
edges of the open arms was calculated from recorded
infrared beam breaks for each 5-min interval of testing. The
main difference in anxiety was found in the first 5 min.
Next, in the novel field test, mice were placed in a open
chamber (16 in.×16 in.) and allowed to explore freely for
15 min. Activity was recorded by an array of infrared
photocells interfaced with a computer (Photobeam Activity
System, San Diego Instruments, San Diego, CA, USA) that
can detect and distinguish horizontal ambulatory movements,
fine movements, and vertical movements (rearing). The center
of the field was defined as the central 4 in.×4 in. square.
Finally, mice were tested in the Morris water maze. Mice were
trained to find a platform (14 cm×14 cm) submerged 1.5 cm
below the surface of the water (18±2°C), made opaque with
nontoxic tempera powder in a 122-cm pool. Mice were
pretrained to remain on the platform in a series of four trials in
which they were placed in a restricted (14 cm×122 cm) alley
within the pool and allowed to swim until they encountered
the platform. If the mouse did not find the platform within
90 s, the mouse was led to the platform by hand, placed on it,
and allowed to sit for 5 s. After 1 day of pretraining, mice were
trained to find a visibly cued platform, marked with a 10-cm-
high, black-and-white striped marker affixed to the center of
the platform. Mice were trained in two daily sessions of two
trials each over three consecutive days. Then, mice were
trained to find a hidden platform in two daily sessions of three
trials each over five consecutive days. For both cued and
hidden platform training, the intertrial interval was 10 min,
and the time between sessions was 3 h. Maximum trial length
was 60 s. Time to reach the platform (latency), path length,
and swim speed were recorded with an EthoVision video
tracking system (Noldus, The Netherlands). Probe trials were
performed 18 h after the 18th and 30th trials of hidden
platform training. For each 60-s probe trial, the platform was
removed from the pool, and the amount of time the mouse
spent searching in the target quadrant was recorded.
Analysis of variance (ANOVA) was performed to detect
the effect of genotype in the elevated plus maze and open
field test. For Morris water maze testing, the main effects
and interactions between genotype and session or probe
trials were assessed by repeated-measures ANOVA.
Plasmid constructs and cell culture
Human COL25A1 cDNA coding region (full-length or with
designed deletion, GeneBank accession no. AF293340,
splice variant without nt952–969) was amplified by PCR,
subcloned into the pEGFPC3 vector (Clontech, BD Bio-
sciences, Mountain View, CA, USA; GenBank accession no.
U57607) and confirmed by sequencing. Constructs were
designated as follows: WT, full-length cDNA coding region;
∆COL1, ∆aa123–162; ∆NC1, ∆aa56–95; ∆NC2, ∆aa165–
188; ∆NC3, ∆aa421–444 (corresponding to GeneBank
accession no. AAK35008). Human neuroblastoma SH-
SY5Y cells (American Type Culture Collection, Manassas,
VA, USA) were cultured in Dulbecco’s modified Eagle’s
medium/F-12 medium (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT, USA) and 100 U/ml penicillin/streptomycin in
a humidified 5% CO2 at 37°C. Lipofectamine 2000
(Invitrogen) was used for transfections. Stable cell lines
were selected with 200 μg/ml geneticin (Invitrogen), induced
to differentiate with 10 μM retinoic acid (Sigma-Aldrich) for
5 days, and harvested for Western blot analysis.
Results
COL25A1 expression in TG mouse brain
TG mice were generated with a human COL25A1 cDNA
driven by the murine Thy1.2 promoter, and two indepen-
dent lines (861 and 797) were maintained. TG human
COL25A1 and endogenous mouse Col25a1 were distin-
guished immunohistochemically with a human-specific
antibody against NC4 (Fig. 1). In 2-month-old TG mice,
cortical neurons stained positively for NC4 primarily in cell
membranes, suggesting that the detected protein was the
precursor form of COL25A1 (Fig. 1a). In 6-month-old TG
mice, NC4 staining of the COL25A1 precursor was strong
in the cortex, CA1 pyramidal neurons, dentate gyrus (DG),
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granule neurons, and thalamic cells (Fig. 1b). Secreted
forms of COL25A1 were detected in extracellular matrix
(ECM) of cortex and DG and formed fibrillar ECM
deposits in 6-month-old mice. In 1-year-old mice, both
forms of COL25A1 were strongly detected in whole brain,
including cortex, hippocampus, and thalamus (Fig. 1c).
These results suggest that the murine Thy1.2 expression
cassette drives COL25A1 expression in a temporal–spatial
pattern beginning in the cortex and progressing to the
hippocampus.
Fig. 1 COL25A1 expression in TG mice begins in cortex and
progresses to hippocampus. a Immunofluorescence staining of 2-
month-old mouse brains. Cortical neurons were stained with NC4
antibody (red) in TG mice but not in WT littermate controls. Sections
were counterstained with DAPI to identify nuclei (blue). b Immuno-
fluorescence staining of 6-month-old mouse brains. Cortex, CA1, and
DG were stained with NC4 antibody (red) in TG mice; the
extracellular secreted form of COL25A1 was also detected in the
DG. WT littermates showed no staining. c Immunohistochemical
staining of 1-year-old mouse brains. NC4 staining was prominent in
cortex, CA1, DG, reticular thalamic nuclei (RT), globus pallidus (GP),
and subiculum in TG but not in WT control mice. Both precursor and
secreted forms of COL25A1 were detected
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Fig. 2 Amyloidosis in COL25A1 TG mice. a Immunohistochemical
staining with Aβ antibody shows prominent Aβ accumulation in the
cortex, CA1, DG, subiculum, reticular thalamic nuclei (RT), and
globus pallidus (GP) in 1-year-old TG mice but not in WT littermates.
b Immunofluorescence and immunohistochemical staining with Aβ
antibody shows punctuate intracellular accumulations in TG mice. WT
littermates displayed only background Aβ staining. c Immunofluo-
rescence and immunohistochemical staining reveals extracellular
protofibrillar Aβ deposits in hippocampal CA1 region in TG mice.
White arrows indicate Aβ clusters; black arrows indicate Aβ patches.
d Extracellular Aβ deposits in 12–16-month-old TG mice (n=7) and
WT controls (n=10)
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COL25A1 triggers amyloidosis in TG mice
To assess pathophysiological changes in the brains of
COL25A1 TG mice, we performed immunohistochemical
staining with an antibody specific for Aβ. Aβ accumulation
occurred concomitantly with the over-expression of
COL25A1 protein and became apparent in TG mice at
1 year of age. Intracellular puncta were seen throughout the
brain, particularly in the cortex, hippocampus, subiculum,
and thalamus (Fig. 2a, b). Extracellular Aβ deposits were
found as individual clusters and in larger patches in the
hippocampus (especially in the CA stratum oriens and
stratum radiatum) and subiculum (Fig. 2c, d). Aβ clusters
were observed in all seven TG mice analyzed at 12–
16 months of age, but in only three (30%) of ten WT
littermates. Aβ patches were present in six TG mice (86%)
but in none of the WT littermates (Fig. 2d).Therefore,
COL25A1 mice exhibited the amyloid accumulations
characteristic of AD.
COL25A1 over-expression leads to behavioral alterations
in TG mice
COL25A1 TG mice were analyzed in three behavioral
assays. In the elevated plus maze test, TG mice spent more
time and traveled farther in the open arms than the WT
controls (Fig. 3a, b), suggesting disinhibition and reduced
anxiety. ANOVA revealed that TG mice spent significantly
more time in the open arms (95.4±14.0 vs. 39.9±7.7 s, F(1,
33)=14.5, p=0.001; 31.8±4.7% vs. 13.3±2.6%, F(1, 33)=
14.5, p=0.001) and traveled farther (423.0±69.6 cm vs.
170.2±27.3 cm, F(1, 33)=15.6, p=0.0004; 26.9±4.1% vs.
11.2±2.1%, F(1, 33)=14.1, p=0.001). Conversely, TG
mice spent less time than WT mice in the closed arms
(153.9±12.4 vs. 206.7±9.2 s, F(1, 33)=11.9, p=0.002;
51.3±4.1% vs. 68.9±3.1%, F(1, 33)=11.9, p=0.002) and
traveled shorter distances (831.5±72.3 vs. 1,091.2±
59.7 cm, F(1, 33)=7.4, p=0.010; 52.7±3.7% vs. 68.1±
2.6%, F(1, 33)=12.5, p=0.001). The numbers of basic and
fine movements did not differ in the two groups (Fig. 3c).
In the open field test, TG mice spent more time
exploring the center area, consistent with data findings in
the elevated plus maze, as reflected in the ratio of central
to peripheral activity (0.204±0.039 vs. 0.120±0.018, F
(1, 33)=5.0, p=0.032, Fig. 3d). Total locomotor activity
was similar in the two groups (Fig. 3e).
In the Morris water maze, COL25A1 TG mice had
significantly slower swim speeds in both the visible
(Fig. 3f) and hidden (Fig. 3g) platform training. Repeated-
measures ANOVA yielded a significant main effect for
genotype in the visible (F(1, 33)=29.4, p<0.001) and
hidden (F(1, 33)=23.1, p<0.001) sessions. The swimming
speed of TG mice was also markedly slower in the probe
trials (14.7±0.9 and 12.6±1.0 cm/s vs. 18.5±0.4 and 17.9±
0.4 cm/s; F(1, 33)=28.1, p<0.001; Fig. 3h). As a result,
latency to reach the platform was longer in TG mice during
the visible sessions (F(1, 33)=4.2, p=0.049) and hidden
sessions (F(1, 33)=6.8, p=0.013; Fig. 1a in Electronic
supplementary material). Spatial learning and memory of
TG mice seemed unimpaired, as the distance crossed in the
training sessions and the search patterns in the probe trials
were similar in the two groups (Fig. 1b, c in Electronic
supplementary material). Thus, apart from the slower
swimming speed of TG mice, both groups performed
similarly in the water maze test.
COL25A1 increases BACE1 and p35/25 expression in TG
mice
To investigate the molecular mechanisms for the amyloid
accumulation and behavioral alterations in COL25A1 TG
mice, we analyzed brain regions for neuronal markers of
AD pathology by Western blotting, immunohistochemical
staining, or both. No differences between groups were
observed in presenilin-1, nNOS, CD1b, calcineurin, 5HT, c-
fos, phosphor-CreB, β catenin, N-cadherin, or connexin-43
(data not shown).
However, TG mice had markedly higher levels of
BACE1 (Fig. 4a) in cortex, hippocampus, thalamus, and
subiculum. BACE1 is believed to be a key player in the
pathogenesis of AD, and changes in its expression or
activity have been reported in AD patients and animal
models that showed aberrant processing of APP and Aβ
accumulation [2, 3] The increase in BACE1 expression was
consistent with the accumulation of Aβ and was prominent
in 1-year-old TG mice.
TG mice also had remarkably higher levels of p35/p25,
the subunit that activates Cdk5, dysfunction of which has
been implicated in AD [8]. Like BACE1, p35/p25
expression was increased in the cortex, hippocampus,
thalamus, and subiculum in 1-year-old TG mice and
paralleled the accumulation of Aβ (Fig. 4b).
Fig. 3 Behavioral alterations of COL25A1 TG mice. a–c In the
elevated plus maze, TG mice spent significantly more time (a) and
traveled longer distances (b) in the open arms than WT littermates.
They also spent less time (a) and traveled smaller distances (b) in the
closed arms. No difference was found between these two groups in the
intersection. Total basic and fine movements of TG mice were not
different from WT littermates (c). d, e In the open field test, TG mice
spent more time exploring the central zone thanWTcontrols, resulting in a
higher ratio of central to peripheral activity (d). Total locomotor activity
was similar in the two groups (e). f–h In the Morris water maze, the
swimming speed of TG mice was significantly slower than that of WT
controls in the visible (f) and hidden (g) platform training sessions and in
the probe trials (h). TG (n=13) and WT littermates (n=22) were used.
Values are mean ± SEM; ***p<0.001, **p<0.01, *p<0.05 (ANOVA)
b
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COL25A1 induces synaptophysin loss and astrocyte
activation in TG mice
The neural dysfunction in AD likely reflects synaptic
damage and disruption of plasticity at synapses. Loss of
synaptic proteins is more severe in AD patients and mouse
models [20, 21]. To determine whether COL25A1 over-
expression induces such abnormalities, we measured the
levels of synaptophysin, a synapse-specific protein, in the
forebrains of 20-month-old mice by Western blotting
(Fig. 4c). Synaptophysin levels were ∼28% lower in TG
mice than WT controls (p=0.05; Fig. 4d), indicating
synapse damage in COL25A1 mice. Since reactive astro-
cytes are often observed in AD brains and mouse models
[22], we looked for astrogliosis in COL25A1 TG mice.
Immunohistochemical analysis revealed increased levels of
staining for GFAP, a marker of astrocyte activation, in the
brains of 16-month-old COL25A1 TG mice, particularly in
the subiculum (Fig. 4e).
NC1, NC2, and NC3 motifs are important for the induction
of BACE1 by COL25A1 in stable cell lines
To further explore the molecular mechanism of COL25A1
in mediating AD-like pathology, we constructed expression
plasmids encoding human full-length COL25A1 (WT) or
COL25A1 with deletions of the COL1 (∆COL1), NC1
(∆NC1), NC2 (∆NC2), or NC3 (∆NC3) domains. Each
construct was transfected into cultured SH-SY5Y cells, and
lines with stable expression were selected. Normal cell
membrane localization was observed in cells over-
expressing WT COL25A1 (Fig. 5a), ∆NC2, and ∆NC3.
However, in cells expressing ∆NC1, COL25A1 was
retained in the cytoplasm, indicating a critical role for the
NC1 motif in normal cellular localization of COL25A1.
Next, we examined BACE1 levels in these cell lines
by Western blotting (Fig. 5b) and densitometry (Fig. 5c).
WT COL25A1 increased BACE1 levels 2.00±0.12-fold
(p=0.001). BACE1 levels were not affected by ∆COL1
and were only slightly reduced from WT levels by ∆NC1
(1.45±0.16-fold, p=0.05), which was mislocalized. How-
ever, the effect of WT COL25A1 was markedly reduced
by ∆NC2 (0.92±0.02-fold, p=0.0008) and ∆NC3 (0.88±
0.13, p=0.003). Together, these results suggested that NC
domains (especially NC2 and NC3) are intimately in-
volved in the induction of BACE1 by COL25A1 protein.
Discussion
This study shows that over-expression of COL25A1 in TG
mice results in prominent accumulation of Aβ and
increased levels of p35/p25 and BACE1. These changes
were accompanied by synaptophysin loss, astrocyte activa-
tion, and alterations on elevated plus maze and open field
test. The NC1, NC2, and NC3 domains of COL25A1 were
important for induction of BACE1 in stably transfected SH-
SY5Y cell lines. Our findings suggest that COL25A1 plays
a critical role in AD pathogenesis, perhaps by acting as an
amyloidogenic cofactor in vivo.
Prominent Aβ accumulation was detected in two
independent COL25A1 transgenic lines (861 and 797) by
immunohistochemical staining with Aβ1-40/42 antibody.
Although it is possible that the detected peptides were Aβ-
containing APP derivatives, these peptides cannot be full-
length APP, as the well-characterized full-length APP
antibody 22C11 did not detect obvious change in these
mice (data not shown).
The intracellular Aβ aggregation could result from
increased production of Aβ, abnormal retention of Aβ
within the secretory system, or enhanced uptake of secreted
Aβ by the endocytic pathway [23]. No obvious change in
APP levels was found in these mice by immunohistochem-
istry. However, BACE1 levels were increased in both TG
lines, suggesting that increased APP processing was
responsible for the Aβ accumulation. BACE1 levels were
also elevated in stably transfected SH-SY5Y cells over-
expressing COL25A1. Since extracellular Aβ deposits were
observed in the mice, it is unlikely that an aberrant
secretory pathway was the major cause of Aβ accumula-
tion. Another possibility is that the membrane-tethered
(precursor) form of COL25A1 favors the internalization of
secreted Aβ by binding to extracellular Aβ aggregates,
resulting in abnormal accumulation of intracellular Aβ.
The extracellular Aβ deposits in COL25A1 TG mice
were clusters or patches evolving into protofibrillar struc-
tures. In contrast to many other AD models, these mice did
not have compact or diffuse plaques at 16 months of age.
Monomeric Aβ is thought to form oligomeric or proto-
fribrillar intermediates that mature into the amyloid fibrils
found in plaques. Evidently, the protofibrillar deposits in
COL25A1 TG mice did not progress to form fibrils in mice
up to 16 months of age. Since secreted COL25A1 builds up
extracellular fibrillar deposits in TG mice, it is possible that
COL25A1 binds to Aβ deposits and slows Aβ fibril
elongation, as suggested by in vitro binding assays [14].
The weaker amyloidogenic ability of mouse Aβ peptides
Fig. 4 Molecular changes in COL25A1 TG mouse brains. a, b
Immunohistochemical staining shows greater BACE1 (a) and p35/p25
(b) immunoreactivity in cortex, CA1, DG, reticular thalamic nuclei
(RT), globus pallidus (GP), and subiculum of TG mice than WT
littermates. c, d Western blot analysis of forebrain extracts shows
synaptophysin loss in TG mice. Values are mean ± SEM; *p<0.05 (t
test). e Immunohistochemical staining of brain sections with anti-
GFAP antibody shows astrocyte activation in the subiculum of TG
mice
b
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might also have contributed to the lack of plaque formation
[24, 25]. It is unlikely that the age of the mice at testing
(16 months) contributed markedly to the lack of plaque
formation, since intracellular Aβ accumulation was appar-
ent as early as 6 months of age, when distinct extracellular
Aβ protofibrillar deposits were seen in one of three TG
mice but in none of three WT littermates. Nonetheless,
further experiments are needed to test whether they will
develop fibrillar plaques at more advanced ages.
In recent years, the amyloid cascade hypothesis has been
modified to reflect experimental evidence that oligomers of
Aβ, not monomers or amyloid fibrils, are the major
initiators of AD pathology. A growing body of report
indicates that oligomeric/protofibrillar Aβ species are toxic
while mature Aβ fibers are largely inert [26–28]. Our
findings in COL25A1 mice support the modified amyloid
hypothesis, which emphasizes the critical role of oligomer-
ic/protofibrillar Aβ accumulation in AD pathology [23, 29].
Although fibrillar plaques did not form in COL25A1 TG
mice, Aβ accumulation induced many of the pathogenic
events proposed by the amyloid cascade hypothesis [1],
including synaptic injury, an inflammatory response, altered
kinase/phosphatase activities, and neuronal dysfunction.
Both synaptophysin loss and astrocyte lesions were
detected in COL25A1 TG mice along with the Aβ
accumulation, indicating abnormalities of neurites. Interest-
ingly, COL25A1 mice had elevated levels of the activator
subunit (p35/p25) of Cdk5 kinase, which has been
implicated in regulating synaptic plasticity, emotionality,
learning, and memory in vivo [30, 31]. COL25A1 mice also
exhibited reduced emotionality or disinhibition in behav-
ioral tests, suggesting neuronal dysfunction. COL25A1
mice spent more time exploring the open arms in the
elevated plus maze and in the center area in the open field
test, indicating reduced anxiety. Similar behaviors have also
been noted in other AD mouse models [32].
Another noticeable behavioral change of COL25A1 mice
was their significantly reduced swimming speed in the
Morris water maze test. To our knowledge, this character-
istic has only been reported in αCamKIIT286A mutant mice,
which might reflect their 129S2/SvHsd hybrid background
[33]. The reduced swimming speed of COL25A1 mice did
not result from floating behavior, since the average speed
was above 10 cm/s in each session. Nor was disturbance of
Fig. 6 Hypothetical model of the AD-like pathogenic process in
COL25A1 mice. Over-expression of COL25A1 (1) leads to increased
p35/p25 levels (2), which promote BACE1 expression and (3)
accelerate Aβ generation and accumulation. 4 Direct binding of
COL25A1 to Aβ exacerbates Aβ accumulation and deposition. 5
Accumulated Aβ causes dysregulation of p35/p25. Together, Aβ
accumulation (6) and dysregulated p35/p25 (7) induce synaptic
dysfunction, which leads to the behavioral changes (8) in COL25A1
TG mice
Fig. 5 NC1, NC2, and NC3 motifs in COL25A1 are important for the
induction of BACE1 by COL25A1. SH-SY5Y cells were stably
transfected with WT, ∆NC1, ∆NC2, or ∆NC3 COL25A1 fused to
EGFP. a WT, ∆NC2, and ∆NC3 proteins showed normal membrane
localization, but ∆NC1 showed aberrant cytoplasmic distribution. b
BACE1 levels in untransfected (SH) and transfected cells. Shown here
is a representative Western blot from three independent experiments.
GAPDH was used as a loading control. c Densitometric quantification
of BACE1 levels relative to level in untransfected cells. Values are
mean ± SEM; ***p<0.001, **p<0.01, *p<0.05 (t test)
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motor function responsible, as locomotor activity in the
elevated plus maze and open field tests was unimpaired,
and COL25A1 mice perform normally in rotarod and
tightrope tests (unpublished data). The slow swimming
speed was evident from the beginning of the test and was
sharply reduced when the platform was removed during the
probe trials. These unique behavioral characteristics might
reflect motivational difficulties.
COL25A1 mice exhibited no deficits in spatial learning
or working memory performance in the water maze test.
This was surprising, considering the prominent, widespread
accumulation of Aβ and increased levels of BACE1 and
p35/p25. The absence of learning and retention deficits in
the water maze has been noted in some AD mouse models
[34, 35], although others did have cognitive deficits [36,
37]. Although the reasons are unclear [38], such discrep-
ancies are likely to be due, in part, to differences in murine
and human physiology and in the toxicity of intracellular
Aβ. Genetic differences in specific species or strains may
substantially modify detectable phenotypes in mouse
models [39]. It is also possible that over-expression of
COL25A1 might activate other pathways to balance the
toxicity of Aβ, thus eliminate the spatial memory deficits
found in some AD models.
Motifs in the NC1, NC2, and NC3 domains of
COL25A1 were important for induction of BACE1 in
stably transfected SH-SY5Y cell lines. Deletion of the NC1
motif caused the protein to lose its ability to traffic to cell
membranes, implying its importance for cellular localiza-
tion. Deletion of the NC2 or NC3 motif did not impair the
trafficking of COL25A1 but attenuated its effect on
BACE1. The NC2 domain harbors one positively charged
amino acid-rich Aβ binding motif that is a predicted
binding domain for heparin [40]. The NC3 domain contains
one coiled-coil motif thought to be necessary for the triple-
helix structure of COL25A1 collagenous fibrils [15]. The
COL1 domain mediates the interaction with Aβ, which
requires COL25A1 to form a triple helix structure [15]. In
stably transfected SH-SY5Y cell lines, deletion of the
COL1 motif did not affect the localization of COL25A1 or
its effect on BACE1 expression. These results suggest that
the integrity and charge state of the protein structure and the
interactions among related proteins contribute to the
pathologic changes caused by COL25A1 over-expression.
Our findings suggest a model in which COL25A1 fulfills
a dual function in the amyloid pathogenesis of AD (Fig. 6).
On the one hand, over-expression of COL25A1 increases
p35/p25 levels, leading to increased BACE1 levels [9, 10],
which promote APP processing, accelerate Aβ generation,
and culminate in intracellular and extracellular accumula-
tion of Aβ. On the other hand, COL25A1 might directly
bind to Aβ aggregates, slow Aβ fibril elongation, and lead
to Aβ aggregation in the toxic protofibrillar intermediary
form. The resulting increase in Aβ toxicity might cause
dysregulation of p35/p25 [5, 6], further increasing Aβ
production through BACE1. Aβ and p35/p25 toxicity
disrupts synaptic activity and induces local inflammatory
response. Ultimately, these changes translate into the
behavioral alterations observed in COL25A1 mice.
Further investigations are needed to test our hypothesis
and determine how COL25A1 induces dysregulation of
p35/p25. Our COL25A1 TG mouse lines will be useful for
exploring the mechanisms involved in the initiation and
progression of AD. In addition, modulation of COL25A1
function may represent a novel therapeutic approach to
prevent or delay the amyloid pathology of AD.
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